**Project title**  
Greater Manchester Community Headache Service

**Project partners**  
Salford Royal Foundation Trust  
Allergan

**Project summary**  
This is a project aimed at improving the management of headache and migraine patients across Greater Manchester through provision of a fully trained nurse specialist led headache service within a community setting. The project will involve repatriating appropriate patients in current headache service and triaging new referrals from GPs and General Neurology, functioning as an intermediate service whilst liaising closely with the main tertiary centre Salford Royal. The community service will provide holistic care for milder patients who will have optimal treatment initiated or continued in line with existing and future NICE Technology Appraisals. Red flag patients will be identified earlier and referred on to appropriate specialists. Quality will be maintained through clinical governance overseen by Salford Royal. Patient outcomes will be monitored and assessed through various methods to demonstrate improvements in patient quality of life scores and enhanced patient experience of care closer to home.

**Expected benefits to patients, the NHS and Allergan**

**Benefits to Patients:**
- Prompt access into a community headache service
- Rapid access to the most appropriate treatments
- Improved patient experience of care closer to home
- Identification of red flags earlier and referral to appropriate specialists
- Better patient understanding of how to manage their condition
- Improvement in patient quality of life scores

**Benefits to NHS:**
- Improved referrals into tertiary centre freeing up Consultants time to see more complex patients
- Potential reduction in non-elective admissions and bed days associated with headache and migraine
- Education of primary care clinicians on management and appropriate referral of patients with headache disorders
- Opportunity to test proof of concept for a community headache service leading to adoption of innovation at scale and pace across Greater Manchester
<table>
<thead>
<tr>
<th>Benefits to Allergan:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Increased appropriate use of medicines, through prescribing and treatment in accordance with relevant NICE TA 260, which may include Allergan medicines.</td>
</tr>
<tr>
<td>• Ability to develop a partnership with a Tertiary Neurology Centre</td>
</tr>
<tr>
<td>• Opportunity to test proof of concept of a successful community model to replicate elsewhere in the UK</td>
</tr>
</tbody>
</table>

| Start Date | October 2018 |